Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Rath, E; Bonelli, M; Duftner, C; Gruber, J; Mandl, P; Moazedi-Furst, F; Pieringer, H; Puchner, R; Flick, H; Salzer, HJF; Weiss, G; Winkler, S; Skvara, H; Moschen, A; Hofer, H; Feurstein, J; Sautner, J.
National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)
WIEN KLIN WOCHENSCHR. 2022;
Doi: 10.1007/s00508-022-02062-7
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Flick Holger
-
Moazedi-Fürst Florentine
-
Salzer Helmut J. F.
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This publication provides a thorough analysis of the most relevant topics concerning the management of latent tuberculosis when using biologic and targeted synthetic Disease Modifying Antirheumatic Drugs (DMARDs) by a multidisciplinary, select committee of Austrian physicians. The committee includes members of the Austrian Societies for Rheumatology and Rehabilitation, Pulmonology, Infectiology, Dermatology and Gastroenterology. Consensus was reached on issues regarding screening and treatment of latent tuberculosis and includes separate recommendations for each biologic and targeted synthetic DMARD.
- Find related publications in this database (Keywords)
-
Tuberculosis
-
Latent tuberculosis
-
Incidence
-
Biologic and targeted synthetic DMARDs
-
Antibiotic regimen